Advanced search
Publication Cover
Drug and Alcohol Review Volume 21, 2002 - Issue 1
Journal homepage
66
Views
15
CrossRef citations to date
0
Altmetric
Research Article

The health effects of ecstasy: a literature review

Linda R. Gowing Drug and Alcohol Services Council, University of Adelaide, South Australia, Australia
,
Susan M. Henry-Edwards Drug and Alcohol Services Council, University of Adelaide, South Australia, Australia
,
Rodney J. Irvine Clinical and Experimental Pharmacology, University of Adelaide, South Australia, Australia
&
Robert L. Ali Drug and Alcohol Services Council, and Clinical and Experimental Pharmacology, University of Adelaide, South Australia, Australia
Pages 53-63 | Published online: 12 Jul 2009

  • Wolff K, Hay AW, Sherlock K & Conner M. Contents of "ecstasy". Lancet 1995;346:1100-1.
  • Anonymous. Ecstasy. NIDA Infofax. National Institute on Drug Abuse, 1999. Available from: http:www.nida.nih.gov/ Infofax/ecstasy.html
  • European Monitoring Centre for Drugs and Drug Addiction. Annual report on the state of the drugs problem in the European Union. Luxembourg: Office for Official Publications of the European Communities, 1999.
  • Topp L, Hando J, Degenhardt L, Dillon P, Roche A, Solowij N. Ecstasy use in Australia. NDARC monograph no. 39. Sydney, Australia: National Drug and Alcohol Research Centre, 1997.
  • McKetin R, Darke S, Hayes A, Rumbold G. Drug Trends 1998. A comparison of drug use and trends in three Australian States: findings from the Illicit Drug Reporting System (IDRS). NDARC monograph no. 41. Sydney, Australia: National Drug and Alcohol Research Centre, 1999.
  • Sherlock K, Conner M. Patterns of ecstasy use amongst club-goers on the UK "dance scene". Int J Drug Policy 1999;10:117-29.
  • Humeniuk R. South Australian Drug Trends 1999. Findings from the Illicit Drug Reporting System. NDARC technical report no. 88. Sydney, Australia: National Drug and Alcohol Research Centre, 2000.
  • Handy C, Pates R, Barrowcliff A. Drug use in South Wales: who uses Ecstasy anyway? J Suhst Misuse 1998;3:82-8.
  • Schifano F. Potential human neurotoxicity of MDMA ("Ecstasy"): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsychobiology 2000;42:25-33.
  • Schuster P, Lieb R, Lamertz C, Wittchen HU. Is the use of ecstasy and hallucinogens increasing? Results from a community study. Eur Addict Res 1998;4:75-82.
  • Topp L, HaIlW, Hando J. Is there a dependence syndrome for ecstasy? NDARC technical report no. 51. Sydney, Australia: National Drug and Alcohol Research Centre, 1997.
  • JansenKL. Ecstasy (MDMA) dependence. Drug Alcohol Depend 1999;53:121-4.
  • Battaglia G, De Souza EB. Pharmacologie profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonergic systems. NIDA Res Monogr 1989;94:240-58.
  • Pierce PA, Peroutka SJ. Ring-substituted amphetamine interactions with neurotransminer receptor binding sites in human cortex. Neurosci Lett 1988;95:208-12.
  • Schloss P, Williams DC. The serotonin transporter: a primary target for antidepressant drugs. J Psychopharmacol 1998;12:115-21.
  • Rawson RA. Treatment for stimulant use disorders. Treatment improvement protocol (TIP) series no. 33. Rockville, Maryland: US Department of Health and Human Services, 1999.
  • Daws L, Irvine RJ, Callaghan PD, Toop PN, White JM, Bochner F. Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:955-77.
  • Malberg JE, Seiden LS. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 1998;18:5086-94.
  • Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
  • Loscher W, Witte U, Fredow G, Ganter M, Bickhardt K. Pharmacodynamic effects of serotonin (5-HT) receptor ligands in pigs: stimulation of 5-HT2 receptors induces malignant hyperthermia. Naunyn-Schmeideberg's Arch Pharmacol 1990;341:483-93.
  • Cohen RS. Subjective reports on the effects of the MDMA (Ecstasy) experience in humans. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:1137-45.
  • Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988;l:273-7.
  • Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (ecstasy) in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998;19:241-51.
  • Peroutka SJ. Recreational use of MDMA. Peroutka SJ, ed. In: Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Boston: Kluwer Academic Publishers, 1990:53-62.
  • Siegel RK. MDMA: nonmedical use and intoxication. J Psychoact Drugs 1986;18:349-54.
  • Mas M, FarreM, de lalbrre R, et al. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 1999;290:136-45.
  • Verebey K. The complications of "ecstasy" (MDMA). JAMA 1988;259:1649-50.
  • de la Torre R, Farre M, Ortuno J, et al. Non-linear pharmacokinetics of MDMA ("ecstasy") in humans. Br J Clin Pharmacol 2000;49:104-9.
  • Tucker GT, Lennard MS, Ellis SW, et al. The demethylenation of methylenedioxymethamphetamine (ecstasy) by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994;47:1151-6.
  • O'Donohoe A, O'Flynn K, Shields K, Hawi Z, Gill M. MDMA toxicity: no evidence for a major influence of metabolic genotype at CYP2D6. Addict Biol 1998;3: 309-14.
  • Schwab M, Seyringer E, Brauer RB, Hellinger A, Griese EU. Fatal MDMA intoxication. Lancet 1999;353: 593-4.
  • Kreth K, Kovar K, Schwab M, Zanger UM. Identification of the human cytochromes P450 involved in the oxidative metabolism of ecstasy-related designer drugs. Biochem Pharmacol 2000;59:1563-71.
  • Coore JR. A fatal trip with ecstasy: a case of 3,4-methylenedioxymethamphetamine/3,4-methylenedioxyamphetamine toxicity. J Roy Soc Med 1996;89:51P-52P.
  • Bingham C, Beaman M, Nicholls AJ, Anthony PP. Necrotizing renal vasculopathy resulting in chronic renal failure after ingestion of methamphetamine and 3,4-methylenedioxyrnetharnphetarnine ("ecstasy"). Nephrol Dial Transplant 1998:13:2654-5.
  • Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 1998;352:1751-2.
  • McCann UD, Eligulashvili V, Ricaurte GA. ( +/-)3,4-Methylenedioxymethamphetanune ("Ecstasy")-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 2000;42:11-16.
  • Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999;19:5096-107.
  • Boot BP, McGregor IS, Hall W. MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 2000;355:1818-21.
  • McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA. Positron emission Homographie evidence of toxic effect of MDMA (ecstasy) on brain serotonin neurons in human beings. Lancet 1998;352:1433-7.
  • Semple DM Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ("ecstasy") users. Br J Psychiatry 1999;175:63-9.
  • Obrocki J, Buchert R, Vaterlein O, Thomasius R, Beyer W, Schiemann T. Ecstasy-long-term effects on the human central nervous system revealed by positron emission tomography. Br J Psychiatry 1999;175:186-8.
  • Chang L, Ernst T, Grob CS, Poland RE. Cerebral (1)H MRS alterations in recreational 3, 4-methylenedioxyme-thamphetamine (MDMA, ecstasy) users. J Magn Reson Imaging 1999;10:521-6.
  • Chang L, Grob CS, Ernst T, et al. Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study. Psycbiatr Res 2000;98:15-28.
  • Reneman L, Hahraken JB, Majoie CB, Booij J, den Heeten GJ. MDMA (ecstasy) and its association with cerebrovascular accidents: preliminary findings. Am J Neuroradiol 2000;21:1001-7.
  • Dafters RI, Duffy F, O'Donnell FJ, Bouquet C. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology (Berlin) 1999;145: 82-90.
  • Gamma A, Frei E, Lehmann D, Pascual-Marqui RD, Hell D, Vollenweider FX. Mood state and brain electric activity in ecstasy users. Neuroreport 2000;11:157-62.
  • Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS. Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology 2000;55:294-6.
  • Curran HV, Travill RA. Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): week-end "high" followed by mid-week low. Addiction 1997;92:821-31.
  • Parrott AC Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology (Berlin) 1998;139:261-8.
  • Klugman A, Hardy S, Baldeweg T, Gruzelier J. Toxic effect of MDMA on brain serotonin neurons. Lancet 1999;3 53:1269-70.
  • Morgan MJ. Recreational use of ecstasy (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology 1998;19:252-64.
  • Parrott AC, Sisk E, Turner JJ. Psychobiological problems in heavy "ecstasy" (MDMA) polydrug users. Drug Alcohol Depend 2000;60:105-10.
  • McCann UD, Ridenour A, Shaham Y, Ricaurte GA. Serotonin neurotoxicity after (+/-)3,4-methylenedioxy-methamphetamine (MDMA; "Ectasy"): a controlled study in humans. Neuropsychopharmacology 1994;10:129-38.
  • Bolla KI, McCann UD, Ricaurte GA. Memory impairment in abstinent MDMA (ecstasy) users. Neurology 1998;51:1532-37.
  • Morgan MJ. Memory deficits associated with recreational use of ecstasy (MDMA). Psychopharmacology (Berlin) 1999;! 41:30-6.
  • McCann UD, MertlM, Eligulashvili V, Ricaurte GA. Cognitive performance in (+/-) 3,4-methyienedioxyme-thamphetamine (MDMA, ecstasy) users: a controlled study. Psychopharmacology (Berlin) 1999;143:417-25.
  • Reneman L, Booij J, Schmand B, van den Brink W, Gunning B. Memory disturbances in ecstasy users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology (Berlin) 2000; 148:3 22-4.
  • WareingM, Fisk JE, Murphy PN. Working memory deficits in current and previous users of MDMA ("cstasy"). Br J Psychol 2000;91:181-8.
  • Gouzoulis-Mayfrank E, Daumann J, Tuchtenhagen F, et al. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J Neurol Neurosurg Psychiatry 2000;68:719-25.
  • Rodgers J. Cognitive performance amongst recreational users of ecstasy. Psychopharmacology (Berlin) 2000;151: 19-24.
  • Colado MI, O'Shea E, Granados R, Murray TK, Green AR. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ("ecstasy") and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol 1997;121:889-900.
  • Aguirre N, Barrionuevo M, Ramirez MJ, Del Rio J, Lasheras B. Alpha-lipoic acid prevents 3,4-methylene-dioxy-methamphetamine (MDMA)-induced neurotoxicity. Neuroreport 1999;10:3675-80.
  • Sprague JE, Everman SL, Nichols DR An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 1998;! 9:427-41.
  • Gerra G, Zaimovic A, FernM, et al. Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol Psychiatry 2000;47:127-36.
  • Bedford Russell AR, Schwartz RH, Dawling S. Accidental ingestion of "Ecstasy" (3,4-methylenedioxymethylamphetamine). Arch Dis Child 1992;67:1114-15.
  • Cooper A, Egleston CV. Accidental ingestion of Ecstasy by a toddler: unusual cause for convulsion in a febrile child. J Accid Emerg Med 1997;14:183-4.
  • Walubo A, Seger D. Fatal multi-organ failure after suicidal overdose with MDMA, "ecstasy": case report and review of the literature. Hum Exp Toxtcol 1999;18:119-25.
  • Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methyienedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology (Berlin) 1995;119:247-60.
  • Henry JA. Ecstasy and the dance of death. BMJ 1992;305:5-6.
  • Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetaniine ("ecstasy"). Lancet 1992;340:384-7.
  • Milroy CM, Clark JC, Forrest AR. Pathology of deaths associated with ecstasy and "eve" misuse. J Clin Pathol 1996;49:149-53.
  • Parr MJ, Low HM, Botterill P. Hyponatraemia and death after ecstasy ingestion. Med J Aust 1997;166: 136-7.
  • O'Connor A, Cluroe A, Couch R, Galler L, Lawrence J, Synek B. Death from hyponatraemia-induced cerebral oedema associated with MDMA (ecstasy) use. NZ Med J 1999;112:255-6.
  • Holden R, Jackson MA. Near-fatal hyponatraemic coma due to vasopressin over-secretion after ecstasy (3,4-MDMA). Lancet 1996;347:1052.
  • White JM, Bochner F, Irvine RJ. The agony of ecstasy. Med J Aust 1997;166:117-18.
  • Henry JA, Fallen JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Low-dose MDMA (ecstasy) induces vasopressin secretion. Lancet 1998;351:1784.
  • Gomez-Balaguer M, Pena H, Morillas C, Hernandez A Syndrome of inappropriate antidiuretic hormone secretion and "designer drugs" (ecstasy). J Pediatr Endocrinol Metab 2000; 13:437-8.
  • Hegadoren KM, Baker GB, Bourin M. 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 1999;23:539-553.
  • Cimbura G. PMA deaths in Ontario. Can Med Assoc J 1974;110:1263-7.
  • Sawyer J, Stephens WP. Misuse of ecstasy. BMJ 1992;305:310.
  • Watson JD, Ferguson C, Hinds CJ, Skinner R, Coakley JH. Exertional heat stroke induced by amphetamine analogues. Does dantrolene have a place? Anaesthesia 1993;48: 1057-60.
  • Byard RW, Gilbert J, James R, Lokan RJ. Amphetamine derivative fatalities in South Australia--is ecstasy the culprit? Aust J Forensic Med Pathol 1998; 19:261-5.
  • Carter N, Rutty GN, Milroy CM, Forrest AR Deaths associated with MBDB misuse. Int J Legal Med 2000;113:168-70.
  • Suarez RV, Riemersma R. Ecstasy and sudden cardiac death. Am J Forensic Med Pathol 1988;9:339-41.
  • Lora-Tamayo C, Tena T, Rodriguez A Amphetamine derivative related deaths. Forensic Sci Int 1997;85: 149-57.
  • Hanyu S, Ikeguchi K, Imai H, Imai N, Yoshida M. Cerebral infarction associated with 3,4-methyienedioxymethamphetamine ("Ecstasy") abuse. Eur Neural 1995;35:173.
  • Gledhill JA, Moore DF, Bell D, Henry JA. Subarachnoid haemorrhage associated with MDMA abuse. J Neural Neurosurg Psychiatry 1993;56:1036-7.
  • Hughes JC, McCabe M, Evans RJ. Intracranial haemorrhage associated with ingestion of "ecstasy". Arch Emerg Med 1993;10:372-4.
  • Jacks AS, Hykin PG. Retinal haemorrhage caused by ecstasy. Br J Ophthalmol 1998;82:842-3.
  • McEvoy AW, Kitchen ND, Thomas DG. Intracerebral haemorrhage caused by drug abuse. Lancet 1998; 351:1029.
  • Harries DP, de Silva R "Ecstasy" and intracerebral haemorrhage. Scott Med J 1992;37:150-2.
  • Dowling GP, McDonough ET, Bost RO. "Eve" and "Ecstasy": a report of five deaths associated with the use of MDEA and MDMA. JAMA 1987;257:1615-17.
  • Forrest AR, Galloway JH, Marsh ID, Strachan GA, Clark JC. A fatal overdose with 3,4-methylenedioxyaniphetamine derivatives. Forensic Sci Int 1994;64:57-9.
  • Weinmann W, Bohnert M. Lethal monointoxication by overdosage of MDEA. Forensic Sci Int 1998;91:91-101.
  • Dowling GP. Human deaths and toxic reactions attributed to MDMA and MDEA. In: Peroutka SJ, ed. Ecstasy: the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Boston: Kluwer Academic Publishers, 1990:63-75.
  • Cadier MA, Clarke JA. Ecstasy and Whizz at a rave resulting in a major burn plus complications. Burns 1993;19:239-40.
  • Davies JP, Evans RO, Newington DP. Ecstasy related trauma. J Accid Emerg Med 1998;15:436.
  • Levine AJ, Drew S, Rees GM. "Ecstasy" induced pneumomediastinum. J Roy Soc Med 1993;86:232-3.
  • Onwudike M. Ecstasy induced retropharyngeal emphysema. J Accid Emerg Med 1996;13:359-61.
  • Rezvani K, Kurbaan AS, Brenton D. Ecstasy induced pneumomediastinum. Thorax 1996;51:960-1.
  • Pittman JA, Pounsford JC. Spontaneous pneumomediastinum and Ecstasy abuse. J Accid Emerg Med 1997;14:335-6.
  • Ahmed JM, Salame MY, Oakley GD. Chest pain in a young girl. Postgrad Med J 1998;74:115-16.
  • Rittoo P, Rittoo DB. Misuse of ecstasy. BMJ 1992;305:309-10.
  • O'Neill D, Dart JK. Methylenedioxyamphetamine ("Ecstasy") associated keratopathy. Eye 1993;7:805-6.
  • Milosevic A, Agrawal N, Redfearn P, Mair L. The occurrence of toothwear in users of Ecstasy (3,4-methylenedioxymethamphetamine). Community Dent Oral Epidemiol 1999;27:283-7.
  • McElhatton PR, Bateman DN, Evans C, Pughe KR, Thomas SH. Congenital anomalies after prenatal ecstasy exposure. Lancet 1999;54:1441-2.
  • Hall AP. Ecstasy and the anaesthetist. Br J Anaesth 1997;79:697-8.
  • Denborough MA, Hopkinson KC. Dantrolene and ecstasy. Med J Aust 1997; 166:165-6.
  • O'Connor B. Hazards associated with the recreational drug Ecstasy. Br J Hosp Med 1994;52):507-14.
  • Tehan B, Hardern R, Bodenham A. Hyperthermia associated with 3,4-methylenedioxyethamphetamine ("Eve"). Anaesthesia 1993;48:507-10.
  • Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology 1999;29:1347-51.
  • Andreu V, Mas A, BrugueraM, et al. Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 1998;29:394-7.
  • Jones AL, Simpson KJ. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment Pharmacol Ther 1999;13:129-33.
  • Ellis AJ, Wendon JA, Portmann B, Williams R. Acute liver damage and ecstasy ingestion. Gut 1996;38:454-8.
  • Fidler H, Dhillon A, Gertner D, Burroughs A. Chronic ecstasy (3,4-methylenedioxymetamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. J Hepatol 1996;25:563-6.
  • Khakoo SI, Coles CJ, Armstrong JS, Barry RE. Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymethamphetamine (ecstasy) usage. J Clin Gastroenterol 1995;20:244-7.
  • Curran HV. Is MDMA ("Ecstasy") neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 2000;42:34-41.
  • Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R. MDMA ("ecstasy") consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 1998;52:85-90.
  • Cohen RS, Cocores J. Neuropsychiatrie manifestations following the use of 3,4-methylenedioxymethamphetamine (MDMA: ecstasy). Prog Neuropsychopharmacol Biol Psychiatry 1997;21:727-34.
  • Benazzi F, Mazzoli M. Psychiatric illness associated with ecstasy. Lancet 1991;338:1520.
  • Pallanti S, Mazzi D. MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry 1992;32:91-5.
  • Williams H, Dratcu L, Taylor R, Roberts M, Oyefeso A. "Saturday night fever": ecstasy related problems in a London accident and emergency department. J Accid Emerg Med 1998;15:322-6.
  • Hardern R, Tehan B. Ecstasy toxicity. J Accid Emerg Med 1995;12:74.
  • Murthy BV, Wilkes RG, Roberts NB. Creatine kinase isoform changes following Ecstasy overdose. Anaesth Intensive Care 1997;25:156-9.
  • Henry JA. Metabolic consequences of drug misuse. Br J Anaesth 2000;85:136-42.
  • Tehan B. Ecstasy and dantrolene. BMJ 1993;306:146.
  • Alciati A, Scaramelli B, Fusi A, Butteri E, Cattaneo ML, Mellado C. Three cases of delirium after ecstasy ingestion. J Psychoactive Drugs 1999;31:167-70.
  • Chenard-Neu MP, Boudjema K, Bernuau J, et al. Auxiliary liver transplantation: regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure--a multicenter European study. Hepatology 1996;23: 1119-27.
  • Topp L, Hando J, Dillon P, Roche A, Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 1999;55:105-15.
  • Hunt N, Jones K, Shelley H. What happens when ecstasy is injected? Int J Drug Policy 1993;4:161-2.
  • Stein DJ, Rink J. Effects of ecstasy blocked by serotonin reuptake inhibitors. J Clin Psychiatry 1999;60:485.
  • Kamieniecki G, Vincent N, Allsop S, Lintzeris N. Models of intervention and care for psychostimulant users. National Drug Strategy monograph series no. 32. Canberra, Australia: Commonwealth Department of Health and Family Services, 1998.
  • Barry KL. Brief interventions and brief therapies for substance abuse. Treatment Improvement Protocol (TIP) series no. 34. Rockville, Maryland: US Department of Health and Human Services, 1999.
  • Williamson S, Gossop M, Powis B, Grimms P, Fountain J, Strang J. Adverse effects of stimulant drugs in a community sample of drug users. Drug Alcohol Depend 1997;44:87-94.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.